Biomedica Italia has signed an agreement with Kuros Biosciences for the distribution of their MagnetOs bone graft throughout Italy.
Kuros Biosciences is a Swiss-headquartered global innovation company with 150 years’ combined research experience in the field of biologics for spinal fusion.
MagnetOs isn’t like other bone grafts. It grows bone even in soft tissue thanks to its unique NeedleGrip™ surface technology which provides traction for our body’s vitally important ‘pro-healing’ (M2 macrophages).*†1,2
This is in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft. *3-5
With this agreement, Biomedica Italia completes the offer of products dedicated to spinal surgery, confirming the interest in the search for innovative solutions and for improving the quality of patient care.”

*Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
†MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.

1. Van Dijk, et al. eCM. 2021;41:756-73.
2. Duan, et al. eCM. 2019;37:60-73.
3. Van Dijk, et al. JOR Spine. 2018;e1039.
4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287.